Demadex Related Published Studies
Well-designed clinical trials related to Demadex (Torsemide)
Torsemide versus furosemide after continuous renal replacement therapy due to acute renal failure in cardiac surgery patients. [2005]
Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. [2001.11]
Long-term efficacy of torsemide compared with frusemide in cirrhotic patients with ascites. [2001.03]
Pharmacodynamics of torsemide administered as an intravenous injection and as a continuous infusion to patients with congestive heart failure. [1996.03]
Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. [1995.06]
Intravenous torsemide as adjunctive therapy in patients with acute pulmonary edema. [1994.11]
Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group. [1994.09]
Dose-response study of intravenous torsemide in congestive heart failure. [1994.08]
A dose-response study of orally administered torsemide in patients with ascites due to cirrhosis. [1994.08]
The pharmacodynamics of torsemide in patients with congestive heart failure. [1994.07]
The pharmacodynamics of intravenous and oral torsemide in patients with chronic renal insufficiency. [1994.07]
The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency. [1994.07]
Six-week study of torsemide in patients with congestive heart failure. [1993.11]
Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis. [1993.07]
Well-designed clinical trials possibly related to Demadex (Torsemide)
The effects of adding torasemide to standard therapy on peak oxygen consumption, natriuretic peptides, and quality of life in patients with compensated left ventricular systolic dysfunction. [2010.07]
The effects of adding torasemide to standard therapy on peak oxygen consumption,
natriuretic peptides, and quality of life in patients with compensated left
ventricular systolic dysfunction. [2010]
TORAFIC study protocol: torasemide prolonged release versus furosemide in patients with chronic heart failure. [2009.08]
Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: comparison with azosemide. [2009.06]
A bioavailability/bioequivalence and pharmacokinetic study of two oral doses of torasemide (5 and 10 mg): prolonged-release versus the conventional formulation. [2009.05]
Comparison of repeated-dose pharmacokinetics of prolonged-release and immediate-release torasemide formulations in healthy young volunteers. [2009.02]
Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. [2009.02]
Comparison of the effects on ambulatory blood pressure of awakening versus bedtime administration of torasemide in essential hypertension. [2008.11]
Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: a randomized noninferiority trial versus torasemide immediate release. [2008.06]
Secondary Pulmonary Hypertension : Haemodynamic Effects of Torasemide versus Furosemide. [2008]
[Efficacy of monotherapy with 15 antihypertensive agents in treating essential hypertension assessed by 24-hour ambulatory blood pressure monitoring] [2007.12]
Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. [2007.09]
Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. [2007.08.28]
[Chronotherapy with torasemide in hypertensive patients: increased efficacy and therapeutic coverage with bedtime administration] [2006.11.18]
Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure. [2006.10]
Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. [2004.06.02]
Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV--efficacy and quality of life. [2003.12]
Role of excess volume in the pathophysiology of hypertension in chronic kidney disease. [2003.11]
A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. [2003.08]
Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. [2003.05]
Intraplatelet calcium levels in patients with acute renal failure before and after the administration of loop diuretics. [2001.03]
Healthcare costs of patients with heart failure treated with torasemide or furosemide. [2000.05]
Loop diuretics in the management of acute renal failure: a prospective, double-blind, placebo-controlled, randomized study. [1997.12]
[Comparison between torasemide and furosemide in the treatment of ascites in cirrhotic patients] [1997.03]
Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites. [1996.10]
Liver cirrhosis with ascites: pathogenesis of resistance to diuretics and long-term efficacy and safety of torasemide. [1994]
Torasemide versus furosemide in cirrhosis: a long-term, double-blind, randomized clinical study. [1993.07]
Advantages of the new loop diuretic torasemide over furosemide in patients with cirrhosis and ascites. A randomized, double blind cross-over trial. [1993.03]
Torasemide in the treatment of patients with cirrhosis and ascites. [1993.01]
Pharmacokinetics and pharmacodynamics of torasemide in patients with chronic renal insufficiency--preliminary evaluation. [1993.01]
Torasemide in the treatment of arterial hypertension. [1993]
Effect of inhaled furosemide and torasemide on bronchial response to ultrasonically nebulized distilled water in asthmatic subjects. [1992.08]
Comparison of the effects of torasemide and furosemide in nonazotemic cirrhotic patients with ascites: a randomized, double-blind study. [1991.06]
Antihypertensive efficacy of low dose torasemide in essential hypertension: a placebo-controlled study. [1988.12]
Assessment of intracellular sodium and calcium in essential hypertension during diuretic treatment. [1988.01]
Acute and chronic effects of torasemide in healthy volunteers. [1988.01]
Pharmacokinetics and metabolism of torasemide in man. [1988.01]
Comparison of efficacy and tolerance of different oral doses of torasemide and furosemide in patients with advanced chronic renal failure. [1988.01]
Torasemide for diuretic treatment of advanced chronic renal failure. [1988.01]
Dose-dependent salidiuretic efficacy of torasemide in comparison to furosemide and placebo in advanced renal failure. [1988.01]
Single dose comparison of torasemide and furosemide in patients with advanced renal failure. [1988.01]
Comparative study on the antihypertensive efficacy of torasemide and indapamide in patients with essential hypertension. [1988.01]
Efficacy and safety of torasemide in patients with chronic heart failure. [1988.01]
Comparative pharmacodynamics of torasemide and furosemide in patients with oedema. [1988.01]
Comparison of diuretic effects and pharmacokinetics of torasemide and furosemide after a single oral dose in patients with hydropically decompensated cirrhosis of the liver. [1988.01]
Renal pharmacodynamic effects of torasemide and furosemide in normal man. [1988.01]
Other research related to Demadex (Torsemide)
Effect of torsemide and furosemide on clinical, laboratory, radiographic and
quality of life variables in dogs with heart failure secondary to mitral valve
disease. [2012]
Reversed-phase ultra-performance liquid chromatographic method development and validation for determination of impurities related to torsemide tablets. [2011.01]
Probable interaction between warfarin and torsemide. [2008.12]
Effects of oral administration of furosemide and torsemide in healthy dogs. [2007.10]
A pharmacoeconomic assessment of torsemide and furosemide in the treatment of patients with congestive heart failure. [1999.05]
Pharmacokinetics of torsemide in patients with decompensated and compensated congestive heart failure. [1998.08]
Photosensitive lichenoid reaction to torsemide--a loop diuretic. [1997.10]
Long-Term Treatment with Oral Torsemide and Its Effect on Body Weight and Fluid Balance in Patients with Chronic Renal Insufficiency. [1996.11]
Torsemide: a new loop diuretic. [1995.08.15]
Torsemide: a pyridine-sulfonylurea loop diuretic. [1995.04]
Other possibly related research studies
Pharmacokinetics and pharmacodynamics of intravenous torasemide in diabetic rats induced by alloxan or streptozotocin. [2005.11]
Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous torasemide in rats. [2005.07.14]
Dose-independent pharmacokinetics of torasemide after intravenous and oral administration to rats. [2005.07]
Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous torasemide in rats. [2003]
A woman with infectious endocarditis caused by Abiotrophia defectiva. [2004.10]
Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein-calorie malnutrition. [2004.09]
Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of torasemide in rabbits. [2004.07]
Food: an unrecognized source of loop diuretic resistance. [2004.05]
[Idiopathic hypereosinophilia with cardiac involvement] [2004.03.12]
Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs). [2004.02.23]
Pharmacotherapy in congestive heart failure: drug absorption in the management of congestive heart failure: loop diuretics. [2003.09]
[Torasemide (Trifas) in clinical practice--own experience] [2003]
[Long-term diuretic treatment in heart failure: are there differences between furosemide and torasemide?] [2002.09.11]
Torasemide in chronic heart failure: results of the TORIC study. [2002.08]
[Torasemide (LUPRAC): a review of its pharmacological and clinical profile] [2001.08]
Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections. [2001]
Failure of the loop diuretic torasemide to improve renal function of hypoxemic vasomotor nephropathy in the newborn rabbit. [2000.04]
Comparison of therapies with torasemide or furosemide in patients with congestive heart failure from a pharmacoeconomic viewpoint. [1998.10]
Clinical pharmacokinetics and pharmacodynamics of torasemide. [1998.01]
High-dose torasemide, given once daily intravenously for one week, in patients with advanced chronic renal failure. [1997.07]
Anticonvulsant activity of pyrid-3-yl-sulfonyl ureas and thioureas. [1997.03]
Urinary excretion profile of torasemide and its diuretic action in dogs. [1996.04]
Effects of furosemide, torasemide and controlled fluid intake on perfluoroisobutene induced lung oedema and mortality. [1996.03]
Benefits and risks of torasemide in congestive heart failure and essential hypertension. [1996.02]
Pharmacoeconomic comparison of loop diuretics in the treatment of congestive heart failure. [1996.01]
Torasemide. An update of its pharmacological properties and therapeutic efficacy. [1995.01]
Treatment of vasogenic brain edema with the novel Cl- transport inhibitor torasemide. [1994.12]
Comparative analysis of torasemide and furosemide in liver cirrhosis. [1994]
Efficacy and tolerance of low-dose loop diuretics in hypertension. [1994]
Role of loop diuretics in chronic renal failure. [1994]
Symptomatic achievements with diuretics in congestive heart failure. [1994]
|
